News

Categories

May 27, 2026

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

May 27, 2026

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

May 8, 2026

Zymeworks to Present at Respiratory Innovation Summit

April 29, 2026

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

April 27, 2026

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

April 21, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

April 9, 2026

Zymeworks to Present at the AACR Oncology Industry Partnering Event

November 4, 2025

Zymeworks Presents New Preclinical Data at the Society for Immunotherapy of Cancer Conference

October 16, 2025

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

October 13, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

October 7, 2025

Zymeworks Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer Annual Meeting

September 26, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the European Respiratory Society Annual Congress